![]() Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Activation of mania, or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder.Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. ![]() Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes.Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range.Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis.Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors. In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. ![]() ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |